KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer
| Image |  |
|---|---|
| Description | scientific article |
| Author/s | |
| Publication date | May 5, 2016 |
| Language | French |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |